MX2023002942A - Formas cristalinas de un inhibidor de kras g12c. - Google Patents

Formas cristalinas de un inhibidor de kras g12c.

Info

Publication number
MX2023002942A
MX2023002942A MX2023002942A MX2023002942A MX2023002942A MX 2023002942 A MX2023002942 A MX 2023002942A MX 2023002942 A MX2023002942 A MX 2023002942A MX 2023002942 A MX2023002942 A MX 2023002942A MX 2023002942 A MX2023002942 A MX 2023002942A
Authority
MX
Mexico
Prior art keywords
crystalline forms
kras
inhibitor
relates
present
Prior art date
Application number
MX2023002942A
Other languages
English (en)
Inventor
Patricia Andres
Cheng Yi Chen
Jennifer Nelson
Samuel Andrew
Susana Del Rio Gancedo
Tawfik Gharbaoui
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2023002942A publication Critical patent/MX2023002942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2- il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2- fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos.
MX2023002942A 2020-09-11 2021-09-10 Formas cristalinas de un inhibidor de kras g12c. MX2023002942A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077553P 2020-09-11 2020-09-11
US202063093673P 2020-10-19 2020-10-19
PCT/US2021/049940 WO2022056307A1 (en) 2020-09-11 2021-09-10 Crystalline forms of a kras g12c inhibitor

Publications (1)

Publication Number Publication Date
MX2023002942A true MX2023002942A (es) 2023-05-22

Family

ID=80629890

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002942A MX2023002942A (es) 2020-09-11 2021-09-10 Formas cristalinas de un inhibidor de kras g12c.

Country Status (12)

Country Link
US (1) US20230357231A1 (es)
EP (1) EP4210833A1 (es)
JP (1) JP2023540809A (es)
KR (1) KR20230137286A (es)
AU (1) AU2021340716A1 (es)
BR (1) BR112023004569A2 (es)
CA (1) CA3190944A1 (es)
CL (1) CL2023000693A1 (es)
CO (1) CO2023004141A2 (es)
IL (1) IL301236A (es)
MX (1) MX2023002942A (es)
WO (1) WO2022056307A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647715B2 (en) * 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019099524A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
MX2022003537A (es) * 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.

Also Published As

Publication number Publication date
JP2023540809A (ja) 2023-09-26
CL2023000693A1 (es) 2023-10-20
US20230357231A1 (en) 2023-11-09
AU2021340716A1 (en) 2023-03-30
IL301236A (en) 2023-05-01
KR20230137286A (ko) 2023-10-04
CA3190944A1 (en) 2022-03-17
WO2022056307A1 (en) 2022-03-17
CO2023004141A2 (es) 2023-08-28
EP4210833A1 (en) 2023-07-19
BR112023004569A2 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2023002942A (es) Formas cristalinas de un inhibidor de kras g12c.
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
IN2012DN02577A (es)
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
MX2010007746A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis.
UA93375C2 (ru) Ингибиторы протеинкиназ ha ochobe замещенных амидов
EP1670466A4 (en) PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EP1689393A4 (en) PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
NZ713828A (en) Crystalline forms of a bruton’s tyrosine kinase inhibitor
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
SE0202463D0 (sv) Novel compounds
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2020010675A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
UA95223C2 (ru) Производные пиридопиримидина, их получение, их применение в терапии
EP4072548A4 (en) COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZINE-1-YL)PYRAZOLO[ 1,5-A]PYRIMIDINE ANALOGUES AS INHIBITORS BY KRAS
WO2007146124A3 (en) Deuterated tadalafil derivatives
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.